GSK Sees Emerging Market Opportunity In Thinking Locally, Developing Locally
This article was originally published in PharmAsia News
Executive Summary
SINGAPORE - GSK APJEM R&D is pretty hefty as far as acronyms go, but GlaxoSmithKline's Judith Hills wants to make sure observers do not over look the research and development title in the new GSK division
You may also be interested in...
GSK's Sandy Macrae On R&D For Emerging Markets: An Interview With PharmAsia News (Part 2 of 2)
GlaxoSmithKline R&D Chairman Moncef Slaoui tasked Sandy Macrae in 2008 to put together a group that would make sure GSK focused some of its R&D efforts on the needs of Asia Pacific and emerging markets. Since then, GSK's APJEM R&D - Asia Pacific, Japan, and Emerging Markets - has been busy pitching the company's established presence in emerging markets to companies looking to expand beyond traditional markets, and even some that aren't. Macrae's lean eight-person team has, in its approach to companies, said that while GSK is looking for later-stage molecules, the group is not opposed to licensing a compound for Asia while its partners pursue Western deals with another company (PharmAsia News, April 9, 2009).
GSK's Sandy Macrae On R&D For Emerging Markets: An Interview With PharmAsia News (Part 2 of 2)
GlaxoSmithKline R&D Chairman Moncef Slaoui tasked Sandy Macrae in 2008 to put together a group that would make sure GSK focused some of its R&D efforts on the needs of Asia Pacific and emerging markets. Since then, GSK's APJEM R&D - Asia Pacific, Japan, and Emerging Markets - has been busy pitching the company's established presence in emerging markets to companies looking to expand beyond traditional markets, and even some that aren't. Macrae's lean eight-person team has, in its approach to companies, said that while GSK is looking for later-stage molecules, the group is not opposed to licensing a compound for Asia while its partners pursue Western deals with another company (PharmAsia News, April 9, 2009).
GSK's Sandy Macrae On R&D For Emerging Markets: An Interview With PharmAsia News (Part 1 Of 2)
GSK's Senior VP Asia Pacific, Japan, and Emerging Markets R&D has been busy pitching the company's established presence in emerging markets to companies looking to expand beyond traditional markets, and even some that aren't.